`Sent:
`To:
`Cc:
`
`Subject:
`
`Dear PTAB Trials,
`
`Miller, Stefan Michael <stefan.miller@kirkland.com>
`Thursday, September 21, 2017 6:46 PM
`Trials
`'Danford, Andrew J'; Hollis, Amanda; *David.Cavanaugh@wilmerhale.com;
`*Robert.gunther@wilmerhale.com; 'abrausa@durietangri.com';
`*DDurie@durietangri.com; 'Pirozzolo, Lisa'; 'Prussia, Kevin S'; 'Allen, Owen';
`#Pfizer_Genentech_IPRs
`IPR2017-01488; IPR2017-01489
`
`Petitioner in the above proceedings, Pfizer Inc., requests a conference call with the Board to seek authorization to:
`
`(1) correct a clerical error in Pfizer’s Petition in IPR2017‐01489, i.e., the omission of claim 65 from the the box
`identifying Proposed Statutory Rejections of the ’213 Patent for Grounds 1 and 2 (IPR2017‐01489, Paper 1 at 5),
`notwithstanding detailed discussion of those grounds for claim 65 is provided in the body of the petition as
`Genentech acknowledged in its Preliminary Response (IPR2017‐01489, Paper 7 at claim 51 n.8 (citing Paper 1 at 51‐
`52)); and
`(2) file replies of no longer than fifteen (15) pages each to Genentech’s Preliminary Responses in IPR2017‐01488 and ‐
`01489 to address certain arguments and evidence submitted by Genentech in its attempt to swear behind certain
`prior art references.
`
`Pfizer has conferred with counsel for Genentech, who indicated that it does not object to request (1) and does not take
`a position with respect to request (2) except that, to the extent that the Board grants a reply, Genentech believes that
`any reply should be no longer than 7 pages and that Genentech should be granted a sur‐reply of equal length.
`
`Counsel for Pfizer and Genentech are available for a conference call with the Board on Tuesday, September 26 between
`12 and 2 ET. Please let us know if there are additional dates for which counsel should provide availability.
`
`Regards,
`
`Stefan M. Miller
`‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐
`KIRKLAND & ELLIS LLP
`601 Lexington Avenue, New York, NY 10022
`T +1 212 446 6479 M +1 917 455 4424
`F +1 212 446 4900
`Conf (US/Can) +18663311856,,,1838339505#
`Conf (Int'l) +12819131081,,,1838339505#
`‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐
`stefan.miller@kirkland.com
`
`The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only
`for the use of the addressee. It is the property of Kirkland & Ellis LLP or Kirkland & Ellis International LLP. Unauthorized use, disclosure or copying of
`this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us
`immediately by return email or by email to postmaster@kirkland.com, and destroy this communication and all copies thereof, including all attachments.
`
`1
`
`